It’s officially been returned to RIGL: finance.yahoo.com/news/Rigel-Assumes-Development-prnews-2774177046.html?x=0&.v=1No impact at all on the stock. I thought it might dip at least a little bit on this ultimate news, notwithstanding the fact that fostamatinib is by far and away the biggest key to the RIGL story.
Market Data 
Markets 
AI
